# Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics

CorpusID: 25728806
 
tags: #Medicine

URL: [https://www.semanticscholar.org/paper/b8df8540458ed7724e3e87f486098d7d66fc6874](https://www.semanticscholar.org/paper/b8df8540458ed7724e3e87f486098d7d66fc6874)
 
| Is Survey?        | Result          |
| ----------------- | --------------- |
| By Classifier     | False |
| By Annotator      | (Not Annotated) |

---

Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics
January/February 1998 33

Kevin R Forward e-mailkevin.forward@dal.ca 
M D Frcpc 
PhDPatricia A Franks 
MDDonald E Low 
FRCPCRobert Rennie 
PhDAndrew E Simor 

Division of Microbiology
Department of Pathology and Laboratory Medicine
Department of Microbiology and Infectious Diseases
Elizabeth II Health Sciences Centre
HalifaxQueen, Nova Scotia


Microbiology and Public Health
Hôpital Maisoneuve-Rosemont
MontréalQuébec


University of Alberta Hospital
EdmontonAlberta


Department of Microbiology
Department of Microbiology
Division of Microbiology, Queen Elizabeth II Health Sciences Centre
Wyeth-Ayerst Canada Inc
Mount Sinai & Princess Margaret Hospitals
Sunnybrook Health Science Centre
5788 University AvenueB3H 1V8Toronto, HalifaxOntario, Nova Scotia

Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics
January/February 1998 33Accepted for publication January 28, 1997. Accepted April 1, 1997MD FRCPC and the Canadian Piperacillin/Tazobactam Study Group Can J Infect Dis Vol 9 No 1 ORIGINAL ARTICLE Correspondence and reprints: Dr Kevin Forward, Service Chief,Antibiotic resistancePiperacillinTazobactamSusceptibility survery
KR Forward, PA Franks, DE Low, R Rennie, AE Simor, and the Canadian Piperacillin/Tazobactam Study Group.Cross-Canada survey of resistance of 2747 aerobic blood culture isolates to piperacillin/tazobactam and other antibiotics. Can J Infect Dis 1998;9(1):33-44.OBJECTIVE:To compare the activity of piperacillin/tazobactam with that of other broad parenteral antibiotics against aerobic and facultative anaerobic blood culture isolates in a Canada-wide survey. DESIGN: Fifty-eight laboratories in nine provinces each contributed up to 50 consecutive clinically significant aerobic and facultative anaerobic isolates for susceptibility testing. SETTING: Participating hospitals included both tertiary care and community hospitals. MATERIALS AND METHODS: Testing was performed in five regional centres by using the same microbroth dilution method, and results were interpreted according to National Commitee for Clinical Laboratory Standards M7-A3 and M100-S5 guidelines. RESULTS: Piperacillin/tazobactam and imipenem were both active against more than 99% of the 1616 strains of Enterobacteriaceae species tested. The minimum inhibitory concentration of 90% of isolates (MIC90) of all Enterobacteriaceae species was 2 mg/L for piperacillin/tazobactam compared with 64 mg/L for piperacillin alone. Seventeen per cent of strains of Enterobacteriaceae species were susceptible to piperacillin/tazobactam but resistant to piperacillin. Piperacillin/tazobactam was highly active against Pseudomonas aeruginosa, inhibiting 99.1% of strains. MIC90 was 8 mg/L. Nine per cent of P aeruginosa strains were not susceptible to imipenem. Most of these strains had a MIC of 8 mg/L, which falls in the intermediate category. Ninety-seven per cent of P aeruginosa were susceptible to ciprofloxacin and 97.3% to tobramycin. Ninety-six per cent of strains of Actinobacter species were susceptible to piperacillin/tazobactam, whereas only 76% of strains were susceptible to piperacillin alone. Overall, piperacillin/tazobactam was the most active agent tested; 98% of all strains were susceptible, followed closely by imipenem, to which 97.8% of strains were susceptible. CONCLUSIONS: Aerobic blood culture isolates from Canadian centres continue to be highly susceptible to a variety of antibiotics. The broad spectrum of activity of piperacillin/tazobactam suggests that this combination should be considered for empirical treatment of sepsis while awaiting results of cultures and susceptibility testing.Piperacillin/tazobactam was the most active agent against P aeruginosa, inhibiting 99.1% of strains; MIC 90 was 8 mg/L. Ninety-one per cent of strains were susceptible to imipenem and 8% had a MIC of 8 mg/L, which fell into the intermediate category. Of the 111 strains of P aeruginosa tested, 97.3% of Can J Infect Dis Vol 9 No 1 January/February 1998 35 Piperacillin/tazobactam resistance Piperacillin/tazobactam resistance

P iperacillin/tazobactam is the most recent of a number of beta-lactam/beta-lactamase inhibitor combinations to become available to Canadian physicians. The combination offers a number of advantages over previously marketed compounds. Piperacillin has a broader spectrum of activity than either the amino or carboxy penicillins, and tazobactam is a potent inhibitor of both chromosomally mediated and plasmid-mediated beta-lactamases (1,2,3).

Numerous clinical trials have demonstrated the efficacy of piperacillin/tazobactam in the treatment of a variety of infections, including intra-abdominal infections, skin and skin structure infections, pelvic infections in women, pneumonia and fever in neutropenic patients undergoing chemotherapy for both solid and hematological malignancies (4)(5)(6)(7)(8)(9)(10)(11)(12)(13). Noncomparative trials have also evaluated the efficacy of piperacillin/tazobactam with or without an aminoglycoside for the treatment of bacteremia (14,15).

We conducted a prospective study of susceptibilities of blood culture isolates collected in 1995 from 58 sites across Canada to determine the prevalence of resistance to commonly used broad spectrum antibiotics, including piperacillin/tazobactam. Such data may help to establish the degree of confidence with which single agents may be used to treat serious bacteremic infections.


## MATERIALS AND METHODS

Strains: Fifty-eight teaching and community hospitals from nine Canadian provinces participated in the evaluation. In most cases, 50 consecutive aerobic cultures were collected, beginning in February 1995. A few smaller centres fell short of this goal. Methicillin-resistant Staphylococcus species and anaerobes were not included. Potential contaminants, such as coagulase-negative Staphylococcus species and viridans streptococci, were submitted only if recovered on three different occasions from the same patient within one week. Only one strain from each species was submitted per patient. Methods: Broth microdilution susceptibility studies were performed with 96-well microtitre plates containing serial twofold dilutions of study antibiotics. Panels were prepared by Sensititre (AccuMed International Inc, Ohio) and distributed to each of five regional testing centres. Organisms were speciated in their originating laboratory by using standard methods. Nonfastidious organisms were tested in accordance with National Committee for Clinical Laboratory Standards (NCCLS) guidelines (NCCLS M7-A3 and M100-S5) (16,17). Inocula were prepared by directly inoculating four to five colonies of an overnight culture of the organism incubated at 35 to 37°C into demineralized water to produce a suspension corresponding to a 0.5 McFarland standard. Ten microlitres of inoculum was suspended in 10 mL of cation-supplemented Mueller Hinton broth. Fifty microlitres of the resulting suspension was transferred to each well of the microtitre plates, which were then incubated aerobically at 34 to 36°C for 18 h.

For susceptibility testing of Streptococcus pneumoniae, the inoculum was prepared in Mueller Hinton broth from overnight growth on 5% sheep blood agar. After mixing, 100 µL of inoculum was added to 10 mL of cation-supplemented Mueller Hinton broth with added 2% to 5% lysed horse blood (PML Microbiological, Oregon). One hundred microlitres was inoculated to each well of the microtitre panel with an autoinoculator. Plates were incubated aerobically at 35°C for 20 to 24 h. Susceptibility testing for streptococci other than S pneumoniae was performed as for S pneumoniae except that only 10 µL was added to 10 mL of Mueller Hinton broth and 50 µL was added to each well.

For Haemophilus influenzae, the inoculum was prepared in 


## RESULTS

Of the 2747 blood culture isolates tested, piperacillin/tazobactam was most active, inhibiting 98% of strains, followed closely by imipenem, which inhibited 97.8% of strains (Table 1). Ceftazidime, ceftriaxone, ciprofloxacin and ticarcillinclavulanate each inhibited over 90% of strains. Overall, the proportion of strains susceptible to third-generation cephalosporins and ciprofloxacin was lower than this percentage, primarily because of their intrinsic inactivity against enterococci, which comprised 160 of 2747 isolates. Against the 1611 strains of Enterobacteriaceae species tested, piperacillin/tazobactam was second only to imipenem in terms of the percentage of strains susceptible; only 0.2% of strains were resistant ( Table 2). The minimum inhibitory concentration of 90% of isolates (MIC 90 ) of Enterobacteriaceae species was 2 mg/L compared with 64 mg/L for piperacillin alone. Seventeen per cent of Enterobacteriaceae species were susceptible to piperacillin/tazobactam but resistant to piperacillin. Enterobacteriaceae species remained highly susceptible to all agents tested, with the exception of piperacillin and cefoxitin, which inhibited 82% and 81% of strains, respectively. Figure 1 compares piperacillin/tazobactam with piperacillin MICs against strains of Enterobacteriaceae species, E coli, Enterobacter cloacae and Acinetobacter species. The majority of strains had lower piperacillin MICs in the presence of tazobactam than with piperacillin alone.        strains were susceptible to ciprofloxacin. Canadian strains remain highly susceptible to aminoglycosides, the MIC 90 for tobramycin being only 1 mg/L. Twenty-five strains of Acinetobacter species were tested and 96% of these were susceptible to piperacillin/tazobactam compared with only 76% of strains susceptible to piperacillin. Only 76% of strains were susceptible to aminoglycosides, and only 68% were susceptible to ceftriaxone. Ceftazidime was somewhat more active than ceftriaxone (MIC 90 8 mg/L versus 64 mg/L) against Acinetobacter species.

All 361 strains of S pneumoniae were susceptible to piperacillin/tazobactam, piperacillin and imipenem. The highest observed piperacillin/tazobactam MIC was 1 mg/L. The highest imipenem MIC was 0.25 mg/L. Only two ceftriaxone-resistant strains (MIC 2 mg/L or greater) were identified. The highest ceftriaxone MIC observed was 8 mg/L. Of the S pneumoniae strains tested, 11.3% had decreased susceptibility to ciprofloxacin (MIC 2 mg/L or greater).

Only three vancomycin-resistant E faecalis strains were identified, and only two of 29 Enterococcus faecium strains 42

Can J Infect Dis Vol 9 No 1 January/February 1998  


## DISCUSSION

The antibiotic armamentarium offers a number of choices for the initial empirical treatment of severely ill patients with bacteremia. The choice of agents in this setting should take into account the observed susceptibility patterns of isolates most frequently encountered. In this study, we compared the activity of a number of broad spectrum antibiotics with Canadian strains collected from both tertiary centres, and community and regional hospitals. With the exception of anaerobes and methicillin-resistant staphylococci, the numbers and proportion of strains tested should be quite representative of the Canadian experience. We have previously made the observation that Canadian strains are often more susceptible to antibiotics than those in Europe and the United States, and, therefore, it is important to use Canadian susceptibility data when making therapeutic choices (18).

Of the agents tested, piperacillin/tazobactam and imipenem had the broadest spectrums of activity. We would also expect these agents to be active against the anaerobes that were recovered during the same period of time but were not tested (19). Of the strains tested, only E faecium and Stenotrophomonas maltophilia were frequently resistant to these agents -E faecium, by virtue of altered penicillin binding proteins and S maltophilia because of its broad spectrum metalloenzyme and decreased permeability.

Piperacillin/tazobactam was much more active against E coli than piperacillin (MIC 90 1 mg/L versus 128 mg/L). Twenty-two per cent more strains were susceptible to piperacillin/tazobactam than to piperacillin alone. This presumably reflects the prevalence of TEM1 beta-lactamases in E coli and their susceptibility to tazobactam (1). For all Enterobacteriaceae species tested, the MIC 90 was lower for piperacillin/tazobactam than for piperacillin. Possibly, this represents a small amount of intrinsic activity of tazobactam, as well as its activity against beta-lactamases from a number of classes. We also observed that E cloacae strains usually had lower MICs to piperacillin/tazobactam than to piperacillin. This has been observed by others and is likely a reflection of the weak activity of tazobactam against class 1 beta-lactamases (20). When piperacillin/tazobactam was compared with ticarcillin-clavulanate, only S maltophilia was more susceptible to ticarcillinclavulanate (MIC 90 64 mg/L versus 256 mg/L). This has been noted by others (21)(22)(23)(24).

A number of agents showed reduced activity against Acinetobacter species. Only 76% of strains were susceptible to gentamicin and tobramycin, and only 71% were susceptible to cefotaxime. Imipenem remained highly active against Acinetobacter species, the MIC 90 being 0.5 mg/L. Ninety-six per cent of strains were susceptible to imipenem. Piperacillin/tazobactam was more active than piperacillin (MIC 90 8 mg/L versus 256 mg/L), and 20% more strains were more susceptible to piperacillin/tazobactam. These findings likely reflect both the intrinsic

## Figure 1 )
1Comparison of the minimal inhibitory concentration (MIC) of piperacillin alone with that of piperacillin/tazobactam (8:1 ratio)


OBJECTIF : Comparer l'activité du pipéracilline/tazobactam à celle d'autres antibiotiques parentéraux à large spectre contre des isolats d'hémocultures aérobies et anaérobies facultatifs dans le cadre d'une enquête pancanadienne. MODÈLE : Cinquante-huit laboratoires de neuf provinces ont chacun fourni jusqu'à 50 isolats aérobies et anaérobies facultatifs cliniquement significatifs aux fins d'épreuves de sensibilité. CONTEXTE : Les hôpitaux participants étaient notamment des centres de soins tertiaires et communautaires. MATÉRIEL ET MÉTHODES : Les épreuves ont été effectuées dans cinq centres régionaux au moyen, des mêmes méthodes de microdilution et les résultats ont été interprétés conformément aux directives M7-A3 et M100-S5 du NCCLS (National Committee for Clinical Laboratory Standards). Haemophilus species test medium and cationsupplemented Mueller Hinton broth. American type culture collection (ATCC) organisms were tested as appropriate, with each batch of organisms run against both Gram-positive and Gram-negative microtitre panels -Staphylococcus aureus ATCC 29213, Enterococcus faecalis ATCC 29212 Escherichia coli ATCC 25922, E coli ATCC 35218 and Pseudomonas aeruginosa ATCC 27853.34 
Can J Infect Dis Vol 9 No 1 January/February 1998 

Forward et al 

Enquête pancanadienne sur la résistance de 2 747 isolats d'hémocultures aérobies à 
l'endroit du pipéracilline/tazobactam et d'autres antibiotiques 

RÉSULTATS : Le pipéracilline/tazobactam et l'imipénem ont tous deux été efficaces contre plus de 99 % des 
1 616 souches d'Enterobacteriaceae testés. Les concentrations inhibitrices minimum de 90 % des isolats (CMI90) de tous 
les Enterobacteriaceae ont été de 2 mg/L pour le pipéracilline/tazobactam contre 64 mg/L pour la pipéracilline seule. 
Seize pour cent des souches d'Enterobacteriaceae se sont révélées sensibles au pipéracilline/tazobactam, mais 
résistantes à la pipéracilline. Le pipéracilline/tazobactam a été très efficace contre Pseudomonas aeruginosa, inhibant 
99,1 % des souches. La CMI90 a été de 8 mg/L; 9 % des souches de P. aeruginosa se sont révélées insensibles à l'imipénem. 
La plupart de ces souches avaient des CMI de 8 mg/L, ce qui les classe dans la catégorie de résistance intermédiaire. 
Quatre-vingt-dix-sept pour cent des isolats de P. aeruginosa ont été sensibles à la ciprofloxacine, 97,3 % à la 
tobramycine. Quatre-vingt-seize pour cent des souches d'Actinobacter ont été sensibles au pipéracilline/tazobactam, 
alors que 76 % seulement des souches étaient sensibles à la pipéracilline seule. Globalement, le pipéracilline/tazobactam 
a été l'agent le plus actif testé. Quatre-vingt-dix-huit pour cent de toutes les souches ont été sensibles, suivi de près par 
l'imipénem auquel 97,8 % des souches ont été sensibles. 
CONCLUSIONS : Les isolats d'hémocultures aérobies provenant de centres canadiens continuent d'être très sensibles à 
divers antibiotiques. Le vaste spectre d'activité du pipéracilline/tazobactam donne à penser que cette association 
médicamenteuse est à envisager en traitement empirique de la septicémie en attendant les résultats des cultures et des 
antibiogrammes. 

Mueller Hinton broth from isolated colonies on chocolate 
agar. Fifty microlitres of inoculum was transferred to 10 mL of 
Haemophilus species test medium broth (HTM) (BBL, Becton 
Dickinson and Company, Maryland). One hundred microlitres 
of HTM was added to each well. Plates were incubated at 35°C 
in carbon dioxide for 20 to 24 h. 
All testing was performed using the same lot number of 
panels, 

## TABLE 1
1Overall proportion of strains susceptible to antibiotics tested against all isolates in rank order% susceptible 

Piperacillin-tazobactam 
98.0 

Piperacillin 
87.5 

Imipenem 
97.8 

Ceftazidime 
91.8 

Ciprofloxacin 
92.8 

Ticarcillin-clavulanate 
90.8 

Ceftriaxone 
91.5 



## TABLE 2
2Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

Escherichia coli (805) 
Piperacillin/tazobactam 
£ 0.25 -³ 256 
0.5 
1 
99.9 
0 
0.1 

Piperacillin 
£ 0.25 -³ 256 
1 
128 
77.8 
8.9 
13.3 

Imipenem 
£ 0.12 -8 
£ 0.12 
£ 0.12 
99.9 
0.1 
0 

Ceftazidime 
£ 0.12 -³ 64 
0.25 
0.5 
97.1 
0.6 
2.2 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
£ 0.12 
98.1 
0.4 
1.5 

Tobramycin 
£ 0.12 -³ 32 
0.25 
1 
98.3 
1 
0.7 

Gentamicin 
£ 0.12 -³ 32 
0.25 
0.5 
97.4 
1.1 
1.5 

Ticarcillin-clavulanate 
£ 0.25 -128 
1 
8 
98.4 
1.5 
0.1 

Ceftriaxone 
£ 0.25 -³ 128 
£ 0.25 
0.5 
97.4 
0.9 
1.7 

Cefotaxime 
£ 0.25 -³ 128 
£ 0.25 
0.5 
97.5 
0.9 
1.6 

Cefoxitin 
£ 0.25 -³ 64 
2 
16 
88.6 
3.7 
7.7 

Klebsiella pneumoniae 
(152) 

Piperacillin/tazobactam 
£ 0.25 -16 
1 
4 
100 
0 
0 

Piperacillin 
0.5 -64 
4 
8 
94.7 
5.3 
0 

Imipenem 
£ 0.12 -8 
£ 0.12 
£ 0.25 
99.3 
0.7 
0 

Ceftazidime 
£ 0.25 -64 
£ 0.25 
1 
96.7 
1.3 
2 

Ciprofloxacin 
£ 0.12 -4 
£ 0.12 
£ 0.12 
98.7 
0.7 
0.7 

Tobramycin 
£ 0.12 -16 
0.25 
0.5 
98 
0.7 
1.3 

Gentamicin 
£ 0.12 -³ 32 
0.25 
0.5 
97.4 
0.7 
2 

Ticarcillin-clavulanate 
£ 0.25 -128 
1 
4 
97.4 
1.3 
1.3 

Ceftriaxone 
£ 0.25 -³ 128 
£ 0.25 
1 
98 
1.3 
0.7 

Cefotaxime 
£ 0.25 -64 
£ 0.25 
0.5 
97.4 
2 
0.7 

Cefoxitin 
0.5 -³ 64 
2 
16 
86.8 
3.9 
9.2 

Klebsiella oxytoca (48) 
Piperacillin/tazobactam 
£ 0.25 -16 
0.5 
2 
100 
0 
0 

Piperacillin 
1 -³ 256 
4 
8 
95.8 
2.1 
2.1 

Imipenem 
£ 0.12 -0.5 
£ 0.12 
0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -16 
£ 0.25 
4 
97.9 
2.1 
0 

Ciprofloxacin 
£ 0.12 -1 
£ 0.12 
0.12 
100 
0 
0 

Tobramycin 
£ 0.12 -2 
0.25 
0.5 
100 
0 
0 

Gentamicin 
£ 0.12 -4 
0.25 
0.5 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -64 
1 
8 
97.9 
2.1 
0 

Ceftriaxone 
£ 0.25 -64 
£ 0.25 
2 
95.8 
2.1 
2.1 

Cefotaxime 
£ 0.25 -64 
£ 0.25 
1 
97.9 
0 
2.1 

Cefoxitin 
0.5 -³ 64 
1 
16 
89.6 
2.1 
8.3 

Citrobacter freundii (9) 
Piperacillin/tazobactam 
0.5 -8 
2 
8 
100 
0 
0 

Piperacillin 
0.5 -64 
2 
64 
77.8 
22.2 
0 

Imipenem 
£ 0.12 -0.5 
£ 0.12 
0.5 
100 
0 
0 

Ceftazidime 
£ 0.25 -32 
£ 0.25 
32 
88.9 
0 
11.1 

Ciprofloxacin 
£ 0.12 -1 
£ 0.12 
1 
100 
0 
0 

Tobramycin 
£ 0.12-0.5 
0.25 
0.5 
100 
0 
0 

Gentamicin 
£ 0.12 -1 
0.25 
1 
100 
0 
0 

Ticarcillin-clavulanate 
0.5 -64 
2 
64 
77.8 
22.2 
0 

Continued on next page 


## TABLE 2
2continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

C freundii 
Ceftriaxone 
£ 0.25 -32 
£ 0.25 
32 
88.9 
11.1 
0 

Cefotaxime 
£ 0.25 -16 
£ 0.25 
16 
88.9 
11.1 
0 

Cefoxitin 
2 -³ 64 
32 
³ 64 
22.2 
11.1 
66.7 

Proteus mirabilis (41) 
Piperacillin/tazobactam 
£ 0.25 -1 
£ 0.25 
0.5 
100 
0 
0 

Piperacillin 
£ 0.25 -8 
£ 0.25 
1 
100 
0 
0 

Imipenem 
£ 0.12 -4 
0.5 
1 
100 
0 
0 

Ceftazidime 
£ 0.25 -1 
£ 0.25 
£ 0.25 
100 
0 
0 

Ciprofloxacin 
£ 0.12 -0.25 
£ 0.12 
£ 0.12 
100 
0 
0 

Tobramycin 
£ 0.12 -16 
0.5 
1 
90.2 
4.9 
4.9 

Gentamicin 
£ 0.12 -16 
0.5 
1 
90.2 
2.4 
7.3 

Ticarcillin-clavulanate 
£ 0.25 -8 
£ 0.25 
1 
100 
0 
0 

Ceftriaxone 
£ 0.25 -2 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefotaxime 
£ 0.25 -1 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefoxitin 
1 -16 
2 
2 
97.6 
2.4 
0 

Enterobacter cloacae 
(77) 

Piperacillin/tazobactam 
£ 0.25 -³ 256 
1 
32 
89.6 
9.1 
1.3 

Piperacillin 
0.5 -³ 256 
2 
128 
76.6 
10.4 
13 

Imipenem 
£ 0.12 -4 
£ 0.12 
0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -³ 64 
£ 0.25 
64 
75.3 
2.6 
22.1 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
0.25 
96.1 
1.3 
2.6 

Tobramycin 
£ 0.12 -16 
0.25 
0.5 
97.4 
0 
2.6 

Gentamicin 
£ 0.12 -8 
£ 0.12 
0.5 
97.4 
2.6 
0 

Ticarcillin-clavulanate 
£ 0.25 -³ 256 
2 
128 
74 
11.7 
14.3 

Ceftriaxone 
£ 0.25 -³ 128 
0.25 
³ 128 
74 
6.5 
19.5 

Cefotaxime 
£ 0.25 -³ 128 
0.25 
³ 128 
74 
7.8 
18.2 

Cefoxitin 
2 -³ 64 
³ 64 
³ 64 
6.5 
3.9 
89.6 

Enterobacter aerogenes 
(16) 

Piperacillin/tazobactam 
£ 0.25 -32 
2 
32 
87.5 
12.5 
0 

Piperacillin 
£ 0.25 -64 
4 
6 4 
7 5 
2 5 
0 

Imipenem 
£ 0.12 -0.5 
£ 0.12 
0.5 
100 
0 
0 

Ceftazidime 
£ 0.25 -³ 64 
£ 0.25 
32 
62.5 
12.5 
25 

Ciprofloxacin 
£ 0.12 -2 
£ 0.12 
0.5 
93.8 
6.3 
0 

Tobramycin 
£ 0.12 -8 
0.25 
2 
93.8 
6.3 
0 

Gentamicin 
£ 0.12 -8 
0.25 
2 
93.8 
6.3 
0 

Ticarcillin-clavulanate 
0.5 -64 
8 
64 
68.8 
31.3 
0 

Ceftriaxone 
£ 0.25 -³ 128 
£ 0.25 
16 
75 
18.8 
6.3 

Cefotaxime 
£ 0.25 -³ 128 
£ 0.25 
8 
93.8 
0 
6.3 

Cefoxitin 
1 -³ 64 
³ 64 
³ 64 
6.3 
12.5 
81.3 

Serratia marcescens (22) Piperacillin/tazobactam 
£ 0.25 -16 
1 
2 
100 
0 
0 

Piperacillin 
£ 0.25 -16 
2 
16 
100 
0 
0 

Imipenem 
£ 0.12 -³ 32 
0.25 
0.5 
95.5 
0 
4.5 

Ceftazidime 
£ 0.25 -1 
£ 0.25 
0.5 
100 
0 
0 

Ciprofloxacin 
£ 0.12 -2 
£ 0.12 
£ 0.12 
95.5 
4.5 
0 

Continued on next page 


## TABLE 2
2continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

S marcescens 
Tobramycin 
£ 0.12 -8 
0.5 
4 
95.5 
4.5 
0 

Gentamicin 
£ 0.12 -8 
0.25 
1 
95.5 
4.5 
0 

Ticarcillin-clavulanate 
1 -128 
4 
32 
86.4 
4.5 
9.1 

Ceftriaxone 
£ 0.25 -8 
£ 0.25 
2 
100 
0 
0 

Cefotaxime 
£ 0.25 -16 
£ 0.25 
8 
90.9 
9.1 
0 

Cefoxitin 
4 -³ 64 
16 
³ 64 
45.5 
22.7 
31.8 

Other 
Enterobacteriaceae 
(39) 

Piperacillin/tazobactam 
£ 0.25 -16 
1 
4 
100 
0 
0 

Piperacillin 
0.5 -³ 256 
1 
64 
89.2 
2.7 
8.1 

Imipenem 
£ 0.12 -0.25 
£ 0.12 
£ 0.12 
100 
0 
0 

Ceftazidime 
£ 0.25 -³ 64 
£ 0.25 
0.5 
94.6 
0 
5.4 

Ciprofloxacin 
£ 0.12 -0.25 
£ 0.12 
£ 0.12 
100 
0 
0 

Tobramycin 
£ 0.12 -1 
0.25 
0.5 
100 
0 
0 

Gentamicin 
£ 0.12 -0.5 
£ 0.12 
0.5 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -32 
1 
8 
94.6 
5.4 
0 

Ceftriaxone 
£ 0.25 -³ 128 
£ 0.25 
8 
94.6 
0 
5.4 

Cefotaxime 
£ 0.25 -³ 128 
£ 0.25 
2 
94.6 
2.7 
2.7 

Cefoxitin 
£ 0.25 -³ 64 
1 
4 
91.9 
0 
8.1 

Morganella morganii (7) Piperacillin/tazobactam 
£ 0.25 -4 
£ 0.25 
4 
100 
0 
0 

Piperacillin 
£ 0.25 -4 
1 
4 
100 
0 
0 

Imipenem 
£ 0.12 -2 
1 
2 
100 
0 
0 

Ceftazidime 
£ 0.25 -³ 64 
£ 0.25 
³ 64 
85.7 
0 
14.3 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
8 
85.7 
0 
14.3 

Tobramycin 
£ 0.25 -16 
0.5 
16 
85.7 
0 
14.3 

Gentamicin 
£ 0.25 -2 
0.5 
2 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -4 
2 
4 
100 
0 
0 

Ceftriaxone 
£ 0.25 -64 
£ 0.25 
64 
85.7 
0 
14.3 

Cefotaxime 
£ 0.25 -16 
£ 0.25 
16 
85.7 
14.3 
0 

Cefoxitin 
4 -³ 64 
4 
³ 64 
85.7 
0 
14.3 

Pseudomonas 
aeruginosa (111) 

Piperacillin/tazobactam 
0.5 -³ 256 
2 
8 
99.1 
0 
0.9 

Piperacillin 
0.5 -³ 256 
4 
16 
96.4 
0 
3.6 

Imipenem 
£ 0.12 -16 
1 
4 
91 
8.1 
0.9 

Ceftazidime 
£ 0.25 -³ 64 
1 
16 
89.2 
6.3 
4.5 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
0.25 
97.3 
0 
2.7 

Tobramycin 
£ 0.12 -³ 32 
0.25 
1 
97.3 
0.9 
1.8 

Gentamicin 
£ 0.12 -³ 32 
0.5 
4 
95.5 
1.8 
2.7 

Ticarcillin-clavulanate 
0.5 -³ 256 
16 
64 
93.6 
0 
6.4 

Pseudomonas species 
(5) 

Piperacillin/tazobactam 
1 -4 
2 
4 
100 
0 
0 

Piperacillin 
4 -³ 256 
4 
³ 256 
80 
0 
20 

Imipenem 
£ 0.25 -1 
0.5 
1 
100 
0 
0 

Ceftazidime 
1 -³ 64 
16 
³ 64 
20 
60 
20 

Ciprofloxacin 
£ 0.12 -4 
£ 0.12 
4 
8 0 
0 
2 0 

Continued on next page 


## TABLE 2
2continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

Pseudomonas species 
Tobramycin 
£ 0.25 -1 
0.5 
1 
100 
0 
0 

Gentamicin 
£ 0.12 -2 
0.5 
2 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -³ 256 
64 
³ 256 
20 
40 
40 

Ceftriaxone 
2 -³ 128 
8 
³ 128 
60 
0 
40 

Cefotaxime 
4 -³ 128 
8 
³ 128 
60 
20 
20 

Cefoxitin 
8 -³ 64 
³ 64 
³ 64 
20 
0 
80 

Acinetobacter species 
(25) 

Piperacillin/tazobactam 
£ 0.25 -32 
0.5 
8 
96 
4 
0 

Piperacillin 
0.5 -³ 256 
8 
³ 256 
76 
12 
12 

Imipenem 
£ 0.12 -³ 32 
£ 0.12 
0.5 
96 
0 
4 

Ceftazidime 
£ 0.25 -³ 64 
2 
8 
9 2 
0 
8 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
8 
8 8 
0 
1 2 

Tobramycin 
£ 0.12 -³ 32 
0.25 
16 
76 
4 
20 

Gentamicin 
£ 0.12 -³ 32 
0.5 
32 
76 
4 
20 

Ticarcillin-clavulanate 
£ 0.25 -128 
4 
6 4 
8 4 
1 2 
4 

Ceftriaxone 
£ 0.25 -³ 128 
8 
6 4 
6 8 
2 0 
1 2 

Cefotaxime 
£ 0.25 -64 
4 
64 
70.8 
16.7 
12.5 

Cefoxitin 
1 -³ 64 
³ 64 
³ 64 
28 
4 
68 

Stenotrophomonas 
maltophilia (13) 

Piperacillin/tazobactam 
8 -³ 256 
8 
³ 256 
61.5 
0 
38.5 

Piperacillin 
8 -³ 256 
32 
³ 256 
38.5 
23.1 
38.5 

Imipenem 
³ 32 
³ 32 
³ 32 
0 
0 
100 

Ceftazidime 
0.5 -³ 64 
2 
³ 64 
84.6 
0 
15.4 

Ciprofloxacin 
£ 0.12 -³ 8 
1 
8 
53.8 
7.7 
38.5 

Tobramycin 
4 -³ 32 
32 
32 
30.8 
15.4 
53.8 

Gentamicin 
2 -³ 32 
32 
32 
15.4 
23.1 
61.5 

Ticarcillin-clavulanate 
4 -128 
8 
64 
76.9 
15.4 
7.7 

Ceftriaxone 
16 -³ 128 
³ 128 
³ 128 
0 
30.8 
69.2 

Cefotaxime 
2 -³ 128 
32 
³ 128 
15.4 
46.2 
38.5 

Cefoxitin 
³ 64 
³ 64 
³ 64 
0 
0 
100 

Haemophilus 
influenzae (27) 

Piperacillin/tazobactam 
£ 0.25 -0.25 
£ 0.25 
0.25 
100 
0 
0 

Piperacillin 
£ 0.25 -64 
£ 0.25 
2 
88.9 
0 
11.1 

Imipenem 
£ 0.12 -0.25 
£ 0.12 
0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -0.25 
£ 0.25 
0.25 
100 
0 
0 

Ciprofloxacin 
£ 0.12 -0.12 
£ 0.12 
£ 0.12 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftriaxone 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefotaxime 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefoxitin 
£ 0.25 -2 
1 
2 
100 
0 
0 

Other Gram-negative 
rods (7) 

Piperacillin/tazobactam 
£ 0.25 -16 
0.5 
16 
100 
0 
0 

Piperacillin 
£ 0.25 -64 
1 
64 
71.4 
28.6 
0 

Imipenem 
£ 0.12 -0.5 
£ 0.12 
0.5 
100 
0 
0 

Ceftazidime 
£ 0.25 -16 
0.5 
16 
85.7 
14.3 
0 

Continued on next page 


## TABLE 2
2continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

Other Gram-negative 
rods (7) 

Ciprofloxacin 
£ 0.12 -0.5 
£ 0.12 
0.5 
100 
0 
0 

Tobramycin 
£ 0.12 -16 
2 
16 
71.4 
0 
28.6 

Gentamicin 
£ 0.12 -16 
1 
16 
71.4 
0 
28.6 

Ticarcillin-clavulanate 
£ 0.25 -32 
£ 0.25 
32 
85.7 
14.3 
0 

Ceftriaxone 
£ 0.25 -8 
£ 0.25 
8 
100 
0 
0 

Cefotaxime 
£ 0.25 -8 
£ 0.25 
8 
100 
0 
0 

Cefoxitin 
£ 0.25 -³ 64 
8 
³ 64 
57.1 
0 
42.9 

Enterococcus faecalis 
(124) 

Piperacillin/tazobactam 
£ 0.25 -32 
2 
4 
96.8 
0 
3.2 

Piperacillin 
£ 0.25 -32 
2 
8 
92.7 
0 
7.3 

Imipenem 
£ 0.25 -³ 32 
1 
2 
96 
0.8 
3.2 

Ciprofloxacin 
£ 0.12 -³ 8 
0.5 
8 
72.6 
2.4 
25 

Ticarcillin-clavulanate 
0.5 -³ 64 
16 
32 
27.4 
0 
72.6 

Vancomycin 
£ 0.25 -³ 64 
1 
1 
97.6 
0 
2.4 

Enterococcus faecium 
(29) 

Piperacillin/tazobactam 
£ 0.25 -32 
32 
32 
34.5 
0 
65.5 

Piperacillin 
£ 0.25 -32 
32 
32 
37.9 
0 
62.1 

Imipenem 
£ 0.25 -³ 32 
32 
32 
37.9 
0 
62.1 

Ciprofloxacin 
£ 0.12 -³ 8 
8 
8 
31 
6.9 
62.1 

Ticarcillin-clavulanate 
£ 0.25 -³ 64 
64 
64 
24.1 
0 
75.9 

Vancomycin 
£ 0.25 -³ 6 
0.5 
2 
99.1 
0 
6.9 

Other enterococci (7) 
Piperacillin/tazobactam 
1 -8 
1 
8 
100 
0 
0 

Piperacillin 
1 -8 
4 
8 
100 
0 
0 

Imipenem 
0.5 -³ 32 
0.5 
³ 32 
85.7 
0 
14.3 

Ciprofloxacin 
£ 0.12 -4 
0.5 
4 
85.7 
0 
14.3 

Ticarcillin-clavulanate 
8 -³ 64 
16 
³ 64 
28.6 
0 
71.4 

Vancomycin 
0.5 -2 
0.5 
2 
100 
0 
0 

Staphylococcus aureus 
(492) 

Piperacillin/tazobactam 
£ 0.25 -32 
0.5 
1 
99.2 
0 
0.8 

Piperacillin 
£ 0.25 -32 
2 
1 6 
8 8 
0 
1 2 

Imipenem 
£ 0.12 -16 
0.25 
0.25 
99.8 
0 
0.2 

Ceftazidime 
£ 0.25 -³ 64 
4 
8 
92.1 
2.6 
5.3 

Ciprofloxacin 
£ 0.12 -³ 8 
£ 0.12 
0.25 
95.9 
0.4 
3.7 

Ticarcillin-clavulanate 
£ 0.25 -128 
1 
4 
94.3 
0 
5.7 

Ceftriaxone 
£ 0.25 -³ 128 
2 
4 
96.7 
2.4 
0.8 

Oxacillin 
£ 0.12 -³ 8 
£ 0.12 
0.5 
97.6 
0 
2.4 

Vancomycin 
£ 0.25 -³ 64 
0.5 
0.5 
99.8 
0 
0.2 

Clindamycin 
£ 0.12 -³ 16 
0.25 
0.5 
90.4 
1.4 
8.1 

Cefuroxime 
£ 0.25 -³ 64 
1 
1 
9 7 
1 
2 

Cefazolin 
£ 0.25 -³ 64 
£ 0.25 
1 
98.6 
0.8 
0.6 

Coagulase-negative 
staphylococci (104) 

Piperacillin/tazobactam 
£ 0.25 -32 
0.5 
8 
91.3 
0 
8.7 

Piperacillin 
£ 0.25 -32 
2 
32 
86.5 
0 
13.5 

Imipenem 
£ 0.25 -³ 32 
£ 0.25 
2 
93.3 
0 
6.7 

Ceftazidime 
£ 0.25 -³ 64 
8 
³ 64 
66.3 
8.7 
25 

Continued on next page 


## TABLE 2
2continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

Coagulase-negative 
staphylococci 

Ciprofloxacin 
£ 0.12 -³ 8 
0.25 
³ 8 
60.6 
6.7 
32.7 

Ticarcillin-clavulanate 
£ 0.25 -128 
0.5 
32 
80.8 
0 
19.2 

Ceftriaxone 
£ 0.25 -³ 128 
4 
64 
81.7 
6.7 
11.5 

Oxacillin 
£ 0.12 -³ 8 
2 
³ 8 
54.8 
0 
45.2 

Vancomycin 
£ 0.25 -2 
0.5 
1 
100 
0 
0 

Clindamycin 
£ 0.25 -³ 16 
³ 16 
³ 16 
42.3 
3.8 
53.8 

Cefuroxime 
£ 0.25 -³ 64 
0.5 
³ 64 
84.6 
1.9 
13.5 

Cefazolin 
£ 0.25 -³ 64 
0.5 
16 
84.6 
6.7 
8.7 

Streptococcus pyogenes 
(54) 

Piperacillin/tazobactam 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Piperacillin 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Imipenem 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Ciprofloxacin 
£ 0.12 -1 
0.25 
0.5 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftriaxone 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Oxacillin 
£ 0.12 -0.25 
£ 0.12 
£ 0.12 
100 
0 
0 

Vancomycin 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Clindamycin 
£ 0.25 -1 
£ 0.25 
£ 0.25 
98.1 
0 
1.9 

Cefuroxime 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefazolin 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Ampicillin 
£ 0.06 -0.25 
£ 0.06 
£ 0.06 
100 
0 
0 

Streptococcus 
agalactiae (81) 

Piperacillin/tazobactam 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Piperacillin 
£ 0.25 -16 
£ 0.25 
£ 0.25 
98.8 
0 
1.2 

Imipenem 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -2 
£ 0.25 
0.5 
95.1 
2.5 
2.5 

Ciprofloxacin 
£ 0.12 -1 
0.25 
0.5 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -4 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftriaxone 
£ 0.25 -1 
£ 0.25 
£ 0.25 
98.8 
1.2 
0 

Oxacillin 
£ 0.12 -1 
£ 0.12 
£ 0.12 
100 
0 
0 

Vancomycin 
£ 0.25 -1 
£ 0.25 
0.5 
100 
0 
0 

Clindamycin 
£ 0.25 -2 
£ 0.25 
£ 0.25 
92.5 
5 
2.5 

Cefuroxime 
£ 0.25 -2 
£ 0.25 
£ 0.25 
100 
0 
0 

Ampicillin 
£ 0.06 -0.25 
£ 0.06 
£ 0.06 
100 
0 
0 

Cefazolin 
£ 0.25 -4 
£ 0.25 
£ 0.25 
100 
0 
0 

Streptococcus 
pneumoniae (361) 

Piperacillin/tazobactam 
£ 0.12 -2 
£ 0.12 
£ 0.12 
100 
0 
0 

Piperacillin 
£ 0.12 -8 
£ 0.12 
£ 0.12 
100 
0 
0 

Imipenem 
£ 0.12 -0.5 
£ 0.12 
£ 0.12 
99.4 
0.6 
0 

Ceftazidime 
£ 0.12 -16 
£ 0.12 
0.5 
90.5 
2.2 
6.9 

Ciprofloxacin 
£ 0.06 -8 
0.5 
2 
88.6 
8.9 
2.5 

Ticarcillin-clavulanate 
£ 0.12 -16 
£ 0.12 
0.25 
96.7 
0 
3.3 


## TABLE 2
2I Intermediate; MIC50 Minimum inhibitory concentration required to inhibit 50% of isolates; MIC90 Minimum inhibitory concentration required to inhibit 90% of isolates; R Resistant; S Susceptible were vancomycin resistant. While piperacillin/tazobactam was highly active against E faecalis, only 34.5% of E faecium strains were susceptible.continued 
Comparative activity of piperacillin/tazobactam and other antibiotics against 2747 aerobic blood culture isolates 

Organism 
(number of strains) 
Antibiotic 
Range (mg/L) MIC50 (mg/L) MIC90 (mg/L) 
% S 
% I 
% R 

S pneumoniae 
Ceftriaxone 
£ 0.12 -8 
£ 0.12 
£ 0.12 
96.4 
2.8 
0.8 

Vancomycin 
£ 0.12 -2 
£ 0.12 
0.5 
99.7 
0 
0.3* 

Clindamycin 
£ 0.12 -16 
£ 0.12 
£ 0.12 
98.6 
0.3 
1.1 

Cefuroxime 
£ 0.12 -4 
£ 0.12 
£ 0.12 
93.6 
1.4 
5 

Cefazolin 
£ 0.12 -4 
£ 0.12 
£ 0.12 
100 
0 
0 

Ampicillin 
£ 0.03 -4 
£ 0.03 
£ 0.12 
93.3 
0 
7.0 

Viridans streptococci 
(40) 

Piperacillin/tazobactam 
£ 0.25 -4 
£ 0.25 
1 
100 
0 
0 

Piperacillin 
£ 0.25 -8 
£ 0.25 
1 
100 
0 
0 

Imipenem 
£ 0.25 -1 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -32 
0.5 
4 
55 
15 
30 

Ciprofloxacin 
£ 0.12 -4 
0.5 
2 
82.5 
15 
2.5 

Ticarcillin-clavulanate 
£ 0.25 -32 
£ 0.25 
8 
9 0 
0 
1 0 

Ceftriaxone 
£ 0.25 -2 
£ 0.25 
1 
87.5 
10 
2.5 

Vancomycin 
£ 0.25 -0.5 
£ 0.25 
0.5 
100 
0 
0 

Clindamycin 
£ 0.25 -0.25 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefuroxime 
£ 0.25 -4 
£ 0.25 
2 
100 
0 
0 

Cefazolin 
£ 0.25 -32 
£ 0.25 
4 
92.5 
5 
2.5 

Ampicillin 
£ 0.06 -³ 4 
£ 0.06 
1 
8 5 
0 
1 5 

Other streptococci (31) Piperacillin/tazobactam 
£ 0.25 -2 
£ 0.25 
£ 0.25 
100 
0 
0 

Piperacillin 
£ 0.25 -2 
£ 0.25 
0.5 
100 
0 
0 

Imipenem 
£ 0.25 -0.5 
£ 0.25 
£ 0.25 
100 
0 
0 

Ceftazidime 
£ 0.25 -³ 64 
£ 0.25 
2 
87.1 
0 
12.9 

Ciprofloxacin 
£ 0.12 -1 
0.25 
0.5 
100 
0 
0 

Ticarcillin-clavulanate 
£ 0.25 -³ 64 
£ 0.25 
£ 0.25 
96.8 
0 
3.2 

Ceftriaxone 
£ 0.25 -32 
£ 0.25 
£ 0.25 
90.3 
3.2 
6.5 

Vancomycin 
£ 0.25 -1 
£ 0.25 
0.5 
100 
0 
0 

Clindamycin 
£ 0.25 -16 
£ 0.25 
£ 0.25 
90.3 
3.2 
6.5 

Cefuroxime 
£ 0.25 -8 
£ 0.25 
£ 0.25 
100 
0 
0 

Cefazolin 
£ 0.25 -16 
£ 0.25 
£ 0.25 
93.5 
6.5 
0 

Ampicillin 
£ 0.06 -³ 4 
£ 0.06 
0.12 
93.5 
0 
6.5 


Piperacillin/tazobactam resistance
Continued on next page
activity of tazobactam against Acinetobacter species and the prevalence of beta-lactamases in Acinetobacter species(1,25).CONCLUSIONSBlood culture isolates from this Canada-wide study remain highly susceptible to a variety of commonly used antibiotics representing several different classes. Piperacillin and tazobactam together inhibited more than 98% of most organism groups tested, including Enterobacteriaceae species, P aeruginosa, H influenzae and streptococci. Piperacillin/tazobactam has a spectrum of activity that provides coverage for bloodstream infections in the vast majority of cases. Other factors, including the result of treatment trials, pharmacokinetics and pharmacoeconomics, will ultimately be required to define the place of piperacillin/tazobactam in the empirical treatment of suspected bacteremia.
. : L Québec, Cote, Centre Hôpital de l'Université Laval, Ste-FoyQuébec: L Cote, Centre Hôpital de l'Université Laval, Ste-Foy;

Centre Hospital Region of Rimouski, Rimouski; M Gourdeau, Hôpital de I'Enfant Jesus, Québec; P Hivon. L Delorme, Charles Lamoyne Hospital, Greenfield Park; P Dolce, Hôpital St François de'Assise, Québec; M Ishak, Hôtel-Dieu de Saint-JéromeSaint-JéromeL Delorme, Charles Lamoyne Hospital, Greenfield Park; P Dolce, Centre Hospital Region of Rimouski, Rimouski; M Gourdeau, Hôpital de I'Enfant Jesus, Québec; P Hivon, Hôpital St François de'Assise, Québec; M Ishak, Hôtel-Dieu de Saint-Jérome, Saint-Jérome;

. P-J Laflamme, Chrdl , Joliette , P-J Laflamme, CHRDL, Joliette;

. M Laverdiere, Maisonneuve-Rosemont, Hospital, Montreal, M Laverdiere, Maisonneuve-Rosemont Hospital, Montreal;

. D Lymand, Longeuil Centre Hospitalier Pierre-Boucher, D Lymand, Centre Hospitalier Pierre-Boucher, Longeuil;

. M Miller, Hospital, ; Montreal, / D Morissette, Lauzon, St-Jean-sur-RichelieuHôpital du Haut RichelieuM Miller, Jewish General Hospital, Montreal; I Morissette/ D Lauzon, Hôpital du Haut Richelieu, St-Jean-sur-Richelieu;

. G Murray, Hôpital du Saint-Sacrement. G Murray, Hôpital du Saint-Sacrement;

. J-F Paradis, Hôpital De Chicoutimi, ; S Chicoutimi, Centre Peloquin, Hospitalier Saint-Michel, Hôpital Pichette, Sacre-Coeur, ; M Montréal, Poisson, de Montréal, MontréalJ-F Paradis, Hôpital de Chicoutimi, Chicoutimi; S Peloquin, Centre Hospitalier Saint-Michel, Montréal; G Pichette, Hôpital Sacre-Coeur, Montréal; M Poisson, Hôtel-Dieu de Montréal, Montréal;

. A Vibien, Reseau Sante Richelieu-Yamaska, Saint-Hyacinthe REFERENCESA Vibien, Reseau Sante Richelieu-Yamaska, Saint-Hyacinthe REFERENCES

A functional classification scheme for b -lactamases and its correlation with molecular structure. K Bush, G A Jacoby, A A Medeiros, Antimicrob Agents Chemother. 39Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for b -lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995;39:1211-33.

Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. H M Bryson, R N Brogden, Drugs. 47Bryson HM, Brogden RN. Piperacillin/tazobactam: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs 1994;47:506-35.

Piperacillin-tazobactam: a critical review of the evolving clinical literature. W E Sanders, C C Sanders, Clin Infect Dis. 22Sanders WE, Sanders CC. Piperacillin-tazobactam: a critical review of the evolving clinical literature. Clin Infect Dis 1996;22:107-23.

Piperacillin/ tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. D M Shlaes, R Baughman, C T Boylen, J Antimicrob Chemother. 3Shlaes DM, Baughman R, Boylen CT, et al. Piperacillin/ tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection. J Antimicrob Chemother 1994;3:565-77.

Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. R L Sweet, S Roy, S Faro, W F O&apos;brien, J S Sanfilippo, M Seidlin, Obstet Gynecol. 83Sweet RL, Roy S, Faro S, O'Brien WF, Sanfilippo JS, Seidlin M. Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. Obstet Gynecol 1993;83:280-5.

Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multi-centre study of piperacillin/tazobactam versus ticarcillin/clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. J S Tan, R M Wishnow, D A Talan, F P Duncanson, C W Norden, Antimicrob Agents Chemother. 37Tan JS, Wishnow RM, Talan DA, Duncanson FP, Norden CW. Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multi-centre study of piperacillin/tazobactam versus ticarcillin/clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group. Antimicrob Agents Chemother 1993;37:1580-6.

Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. Y Moulton, O Leroy, C Beuscart, J Antimicrob Chemother. 31Suppl AMoulton Y, Leroy O, Beuscart C. Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections. J Antimicrob Chemother 1993;31(Suppl A):87-95.

Piperacillin/tazobactam in the treatment of polymicrobial infections. S L Gorbach, Intensive Care Med. 20Gorbach SL. Piperacillin/tazobactam in the treatment of polymicrobial infections. Intensive Care Med 1994;20:S27-34.

Piperacillin/tazobactam in complicated urinary tract infections. P Nowe, Intensive Care Med. 203SupplNowe P. Piperacillin/tazobactam in complicated urinary tract infections. Intensive Care Med 1994;20(Suppl 3):S39-42.

Piperacillintazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections. D Brismar, A S Malmborg, G Tunevall, Antimicrob Agents Chemother. 36Brismar D, Malmborg AS, Tunevall G, et al. Piperacillin- tazobactam versus imipenem-cilastatin in the treatment of intra-abdominal infections. Antimicrob Agents Chemother 1992;36:2766-74.

Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infection. J Niinikoski, T Havia, E Alhava, Surg Gynecol Obstet. 176Niinikoski J, Havia T, Alhava E et al. Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infection. Surg Gynecol Obstet 1993;176:255-61.

Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. A Cometta, S Zinner, R De Bock, Antimicrob Agents Chemother. 39Cometta A, Zinner S, de Bock R, et al. Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother 1995;39:445-52.

Piperacillin/tazobactam/ amikacin versus piperacillin/amikacin/tiecoplanin in the empirical treatment of neutropenic patients. A Micozzi, M Nucci, M Venditti, Eur J Clin Microbiol Infect Dis. 12Micozzi A, Nucci M, Venditti M, et al. Piperacillin/tazobactam/ amikacin versus piperacillin/amikacin/tiecoplanin in the empirical treatment of neutropenic patients. Eur J Clin Microbiol Infect Dis 1993;12:1-8.

The efficacy and safety of piperacillin/tazobactam in the therapy of bacteremia. R Wise, J Antimicrob Chemother. 31Suppl AWise R. The efficacy and safety of piperacillin/tazobactam in the therapy of bacteremia. J Antimicrob Chemother 1993;31 (Suppl A):97-104.

Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. P Charbonneau, Intensive Care Med. 20Charbonneau P. Review of piperacillin/tazobactam in the treatment of bacteremic infections and summary of clinical efficacy. Intensive Care Med 1994;20:S43-8.

(NCCLS) methods for dilution antimicrobial susceptility tests for bacteria that grow aerobically: approved standard M7-A3. Villanova. National Committee for Clinical Laboratory StandardsNational Committee for Clinical Laboratory Standards (NCCLS) methods for dilution antimicrobial susceptility tests for bacteria that grow aerobically: approved standard M7-A3. Villanova, 1993.

National Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: 5th Informational Supplement. VillanovaNational Committee for Clinical Laboratory Standards (NCCLS) Performance standards for antimicrobial susceptibility testing: 5th Informational Supplement, M100-S5. Villanova, 1994.

Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. K R Forward, D E Low, M Laverdiere, Can J Infect Dis. 8Forward KR, Low DE, Laverdiere M, et al. Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Can J Infect Dis 1997;8:147-53.

Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. P C Appelbaum, S K Spangler, M R Jacobs, J Antimicrob Chemother. 32Appelbaum PC, Spangler SK, Jacobs MR. Susceptibility of 539 gram-positive and gram-negative anaerobes to new agents, including RP59500, biapenem, trospectomycin and piperacillin/tazobactam. J Antimicrob Chemother 1993;32:223-31.

Interactions of tazobactam and clavulanate with inducibly and constitutively expressed Class I beta-lactamases. M Akova, Y Yang, D M Livermore, J Antimicrob Chemother. 25Akova M, Yang Y, Livermore DM. Interactions of tazobactam and clavulanate with inducibly and constitutively expressed Class I beta-lactamases. J Antimicrob Chemother 1990;25:199-208.

Activity of ticarcillin/clavulanate and piperacillin/tazobactam. C C Knapp, J Sierra-Madero, J A Washington, YTR 830Knapp CC, Sierra-Madero J, Washington JA. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830;

CL-298, 741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis. 12CL-298, 741) against clinical isolates and against mutants derepressed for class I beta-lactamase. Diagn Microbiol Infect Dis 1989;12:511-5.

Comparative in vitro activities of piperacillintazobactam and ticarcillin-clavulanate. R J Fass, R B Prior, Antimicrob Agents Chemother. 33Fass RJ, Prior RB. Comparative in vitro activities of piperacillin- tazobactam and ticarcillin-clavulanate. Antimicrob Agents Chemother 1989;33:1268-74.

Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). G M Eliopoulos, K Klimm, M J Ferraro, G A Jacoby, R C MoelleringJr, Diagn Microbiol Infect Dis. 12Eliopoulos GM, Klimm K, Ferraro MJ, Jacoby GA, Moellering RC Jr. Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830). Diagn Microbiol Infect Dis 1989;12:481-8.

Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of b -lactam/b -lactamase inhibitor combinations. J A Garcia-Rodriguez, Garcia Sanchez, J E , Garcia Garcia, M I , Garcia Sanchez, E , Munoz Bellido, J L , Diagn Microbiol Infect Dis. 14Garcia-Rodriguez JA, Garcia Sanchez JE, Garcia Garcia MI, Garcia Sanchez E, Munoz Bellido JL. Antibiotic susceptibility profile of Xanthomonas maltophilia in vitro activity of b -lactam/b -lactamase inhibitor combinations. Diagn Microbiol Infect Dis 1991;14:239-43.

In vitro activity of b -lactamase inhibitors against clinical isolates of Acinetobacter species. B Suh, T Shapiro, R Jones, V Satishchandran, A L Truant, Diagn Microbiol Infect Dis. 21Suh B, Shapiro T, Jones R, Satishchandran V, Truant AL. In vitro activity of b -lactamase inhibitors against clinical isolates of Acinetobacter species. Diagn Microbiol Infect Dis 1995;21:111-4.